Pursuing novel mechanisms for treating cancer and validating them with clinical trials has paid off for drug developers, especially as the FDA is speeding up approvals of new treatments for unmet medical needs, a Tufts report concluded.
Pursuing novel mechanisms for treating cancer and validating them with clinical trials has paid off for drug developers, especially as the FDA is speeding up approvals of new treatments for unmet medical needs, a Tufts report concluded.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
![[column] Toekomst tijdschriften glanst als nooit tevoren](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/happy-couple-in-t-shirts-reading-newspaper-while-h-2024-11-10-00-13-23-utc-1-80x60.jpg)
![[column] MarketingAffairs 17: Marketing als oplossing](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/asian-seo-manager-writing-on-glass-with-illustrati-2024-11-17-23-11-51-utc-1-80x60.jpg)
